Top

Published in:

01-12-2008

Imaging of tumor glucose utilization with positron emission tomography

Authors: Andrea Buerkle, Wolfgang A. Weber

Published in: Cancer and Metastasis Reviews | Issue 4/2008

Abstract

In recent years, imaging of tumor glucose metabolism with positron emission tomography and fluorodeoxyglucose (FDG-PET) has become a routine test for detection, staging and restaging of malignant lymphomas and many solid tumors. FDG-PET is also increasingly used to monitor the effects of chemotherapy. The success of FDG-PET in oncologic imaging has generated considerable interest in understanding the molecular mechanisms underlying the markedly accelerated glucose use of almost all human cancers. Recent studies have indicated that there may be a close relation between the activation of oncogenic signaling pathways and cellular glucose utilization. For example deregulation of Akt, ras and MYC as well as loss of p53 function have been reported to confer increased glucose metabolic rates in cancer cells. These findings suggest that imaging of tumor glucose utilization may represent a marker for the activity of oncogenic pathways and metabolic changes during therapy may be used as a readout for the effectiveness of drugs targeting these pathways. However, the mechanisms for increased glucose metabolic activity of cancers cells are multifactorial and clinical studies will be necessary to determine in which context imaging of tumor glucose metabolism may be used for treatment monitoring.

Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., et al. (2007). Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579–586.PubMedCrossRef

IMV (2006). 2005/06 PET market summary report. IMV Medical Information Division: Des Plaines.

Warburg, O., Posener, K., & Negelein, E. (1924). Ueber den Stoffwechsel von Tumoren. Biochemische Zeitschrift, 152, 319–344.

Czernin, J., Allen-Auerbach, M., & Schelbert, H. R. (2007). Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. Journal of Nuclear Medicine, 48(Suppl 1), 78S–88S.PubMed

Israel, O., & Kuten, A. (2007). Early detection of cancer recurrence: ¹⁸F-FDG PET/CT can make a difference in diagnosis and patient care. Journal of Nuclear Medicine, 48(Suppl 1), 28S–35S.PubMed

Bunyaviroch, T., & Coleman, R. E. (2006). PET evaluation of lung cancer. Journal of Nuclear Medicine, 47, 451–469.PubMed

Seam, P., Juweid, M. E., & Cheson, B. D. (2007). The role of FDG-PET scans in patients with lymphoma. Blood, 110, 3507–3516.PubMedCrossRef

Weber, W. A. (2005). Use of PET for monitoring cancer therapy and for predicting outcome. Journal of Nuclear Medicine, 46, 983–995.PubMed

Rich, P. R. (2003). The molecular machinery of Keilin’s respiratory chain. Biochemical Society Transactions, 31, 1095–1105.PubMedCrossRef

10.

Van Schaftingen, E., Jett, M. F., Hue, L., & Hers, H. G. (1981). Control of liver 6-phosphofructokinase by fructose 2,6-bisphosphate and other effectors. Proceedings of the National Academy of Sciences of the United States of America, 78, 3483–3486.PubMedCrossRef

11.

Telang, S., Yalcinm, A., Clem, A. L., Bucala, R., Lane, A. N., Eaton, J. W., et al. (2006). Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene, 25, 7225–7234.PubMedCrossRef

12.

Huang, S. C. (2000). Anatomy of SUV. Standardized uptake value. Nuclear Medicine and Biology, 27, 643–646.PubMedCrossRef

13.

Weber, W. A., Petersen, V., Schmidt, B., Tyndale-Hines, L., Link, T., Peschel, C., et al. (2003). Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. Journal of Clinical Oncology, 21, 2651–2657.PubMedCrossRef

14.

Vesselle, H., Schmidt, R. A., Pugsley, J. M., Li, M., Kohlmyer, S. G., Vallires, E., et al. (2000). Lung cancer proliferation correlates with [F-¹⁸]fluorodeoxyglucose uptake by positron emission tomography. Clinical Cancer Research, 6, 3837–3844.PubMed

15.

Buck, A., Halter, G., Schirrmeister, H., Kotzerke, J., Wurziger, I., Glatting, G., et al. (2003). Imaging proliferation in lung tumors with PET: ¹⁸F-FLT versus ¹⁸F-FDG. Journal of Nuclear Medicine, 44, 1432–1434.

16.

van Baardwijk, A., Dooms, C., van Suylen, R. J., Verbeken, E., Hochstenbag, M., Dehing-Oberije, C., et al. (2007). The maximum uptake of ⁽¹⁸⁾F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. European Journal of Cancer, 43, 1392–1398.PubMedCrossRef

17.

Yap, C. S., Czernin, J., Fishbein, M. C., Cameron, R. B., Schiepers, C., Phelps, M. E., et al. (2006). Evaluation of thoracic tumors with ¹⁸F-fluorothymidine and ¹⁸F-fluorodeoxyglucose-positron emission tomography. Chest, 129, 393–401.PubMedCrossRef

18.

Di Chiro, G. (1987). Positron emission tomography using [¹⁸F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Investigative Radiology, 22, 360–371.PubMedCrossRef

19.

Folpe, A. L., Lyles, R. H., Sprouse, J. T., Conrad 3rd, E. U., & Eary, J. F. (2000). (F-¹⁸) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clinical Cancer Research, 6, 1279–1287.PubMed

20.

Kole, A. C., Nieweg, O. E., Hoekstra, H. J., van Horn, J. R., Koops, H. S., & Vaalburg, W. (1998). Fluorine-¹⁸-fluorodeoxyglucose assessment of glucose metabolism in bone tumors. Journal of Nuclear Medicine, 39, 810–815.PubMed

21.

Fulham, M. J., Melisi, J. W., Nishimiya, J., Dwyer, A. J., & Di Chiro, G. (1993). Neuroimaging of juvenile pilocytic astrocytomas: an enigma. Radiology, 189, 221–225.PubMed

22.

Bos, R., van Der Hoeven, J. J., van Der Wall, E., van Der Groep, P., van Diest, P. J., Comans, E. F., et al. (2002). Biologic correlates of ⁽¹⁸⁾fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. Journal of Clinical Oncology, 20, 379–387.PubMedCrossRef

23.

Westerterp, M., Sloof, G. W., Hoekstra, O. S., Ten Kate, F. J., Meijer, G. A., Reitsma, J. B., et al. (2008). ⁽¹⁸⁾FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. Journal of Cancer Research and Clinical Oncology, 134, 227–236.PubMedCrossRef

24.

Yen, T. C., See, L. C., Lai, C. H., Yah-Huei, C. W., Ng, K. K., Ma, S. Y., et al. (2004). ¹⁸F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. Journal of Nuclear Medicine, 45, 22–29.PubMed

25.

Tohma, T., Okazumi, S., Makino, H., Cho, A., Mochiduki, R., Shuto, K., et al. (2005). Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer. Hepato-Gastroenterology, 52, 486–490.PubMed

26.

Yamada, K., Brink, I., Bisse, E., Epting, T., & Engelhardt, R. (2005). Factors influencing [F-¹⁸] 2-fluoro-2-deoxy-d-glucose (F-18 FDG) uptake in melanoma cells: the role of proliferation rate, viability, glucose transporter expression and hexokinase activity. Journal of Dermatology, 32, 316–334.PubMed

27.

Mamede, M., Higashi, T., Kitaichi, M., Ishizu, K., Ishimori, T., Nakamoto, Y., et al. (2005). [¹⁸F]FDG uptake and PCNA, glut-1, and hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia, 7, 369–379.PubMedCrossRef

28.

de Geus-Oei, L. F., van Krieken, J. H., Aliredjo, R. P., Krabbe, P. F., Frielink, C., Verhagen, A. F., et al. (2007). Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer, 55, 79–87.PubMedCrossRef

29.

Aloj, L., Caraco, C., Jagoda, E., Eckelman, W. C., & Neumann, R. D. (1999). Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Research, 59, 4709–4714.PubMed

30.

Gatenby, R. A., & Gillies, R. J. (2008). A microenvironmental model of carcinogenesis. Nature Reviews Cancer, 8, 56–61.PubMedCrossRef

31.

Kim, J. W., Gao, P., & Dang, C. V. (2007). Effects of hypoxia on tumor metabolism. Cancer and Metastasis Reviews, 26, 291–298.PubMedCrossRef

32.

Zhang, H., Gao, P., Fukuda, R., Kumar, G., Krishnamachary, B., Zeller, K. I., et al. (2007). HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell, 11, 407–420.PubMedCrossRef

33.

Kim, J. W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006). HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metabolism, 3, 177–185.PubMedCrossRef

34.

Semenza, G. L., Roth, P. H., Fang, H. M., & Wang, G. L. (1994). Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. Journal of Biological Chemistry, 269, 23757–23763.PubMed

35.

Carmeliet, P., Dor, Y., Herbert, J. M., Fukumura, D., Brusselmans, K., Dewerchin, M., et al. (1998). Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature, 394, 485–490.PubMedCrossRef

36.

Riddle, S. R., Ahmad, A., Ahmad, S., Deeb, S. S., Malkki, M., Schneider, B. K., et al. (2000). Hypoxia induces hexokinase II gene expression in human lung cell line A549. American Journal of Physiology. Lung Cellular and Molecular Physiology, 278, L407–L416.PubMed

37.

Burgman, P., Odonoghue, J. A., Humm, J. L., & Ling, C. C. (2001). Hypoxia-induced increase in FDG uptake in MCF7 cells. Journal of Nuclear Medicine, 42, 170–175.PubMed

38.

Clavo, A. C., Brown, R. S., & Wahl, R. L. (1995). Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. Journal of Nuclear Medicine, 36, 1625–1632.PubMed

39.

Cherk, M. H., Foo, S. S., Poon, A. M., Knight, S. R., Murone, C., Papenfuss, A. T., et al. (2006). Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by ¹⁸F-fluoromisonidazole and ¹⁸F-FDG PET. Journal of Nuclear Medicine, 47, 1921–1926.PubMed

40.

Rajendran, J. G., Mankoff, D. A., O'Sullivan, F., Peterson, L. M., Schwartz, D. L., Conrad, E. U., et al. (2004). Hypoxia and glucose metabolism in malignant tumors: evaluation by [¹⁸F]fluoromisonidazole and [¹⁸F]fluorodeoxyglucose positron emission tomography imaging. Clinical Cancer Research, 10, 2245–2252.PubMedCrossRef

41.

Rajendran, J. G., Wilson, D. C., Conrad, E. U., Peterson, L. M., Bruckner, J. D., Rasey, J. S., et al. (2003). [⁽¹⁸⁾F]FMISO and [⁽¹⁸⁾F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. European Journal of Nuclear Medicine and Molecular Imaging, 30, 695–704.PubMed

42.

Shim, H., Dolde, C., Lewis, B. C., Wu, C. S., Dang, G., Jungmann, R. A., et al. (1997). c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proceedings of the National Academy of Sciences of the United States of America, 94, 6658–6663.PubMedCrossRef

43.

Kim, J. W., & Dang, C. V. (2006). Cancer’s molecular sweet tooth and the Warburg effect. Cancer Research, 66, 8927–8930.PubMedCrossRef

44.

Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nature Reviews Cancer, 3, 721–732.PubMedCrossRef

45.

Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., et al. (2000). Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes and Development, 14, 34–44.PubMed

46.

Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., et al. (2000). Loss of PTEN facilitates HIF-1-mediated gene expression. Genes and Development, 14, 391–396.PubMed

47.

Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M. M., et al. (2000). Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Research, 60, 1541–1545.PubMed

48.

Jiang, B. H., Agani, F., Passaniti, A., & Semenza, G. L. (1997). V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Research, 57, 5328–5335.PubMed

49.

Fukuda, R., Hirota, K., Fan, F., Jung, Y. D., Ellis, L. M., & Semenza, G. L. (2002). Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. Journal of Biological Chemistry, 277, 38205–38211.PubMedCrossRef

50.

Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001). HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Molecular and Cellular Biology, 21, 3995–4004.PubMedCrossRef

51.

Liu, X. H., Kirschenbaum, A., Lu, M., Yao, S., Dosoretz, A., Holland, J. F., et al. (2002). Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. Journal of Biological Chemistry, 277, 50081–50086.PubMedCrossRef

52.

Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F., & Maity, A. (2001). Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. Journal of Biological Chemistry, 276, 9519–9525.PubMedCrossRef

53.

Blum, R., Jacob-Hirsch, J., Amariglio, N., Rechavi, G., & Kloog, Y. (2005). Ras inhibition in glioblastoma downregulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Research, 65, 999–1006.PubMed

54.

Chesney, J. (2006). 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis. Current Opinion in Clinical Nutrition and Metabolic Care, 9, 535–539.PubMedCrossRef

55.

Zdychova, J., & Komers, R. (2005). Emerging role of Akt kinase/protein kinase B signaling in pathophysiology of diabetes and its complications. Physiological Research, 54, 1–16.PubMed

56.

Thompson, J. E., & Thompson, C. B. (2004). Putting the rap on Akt. Journal of Clinical Oncology, 22, 4217–4226.PubMedCrossRef

57.

Plas, D. R., & Thompson, C. B. (2005). Akt-dependent transformation: there is more to growth than just surviving. Oncogene, 24, 7435–7442.PubMedCrossRef

58.

Majewski, N., Nogueira, V., Bhaskar, P., Coy, P. E., Skeen, J. E., Gottlob, K., et al. (2004). Hexokinase–mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Molecular Cell, 16, 819–830.PubMedCrossRef

59.

Pastorino, J. G., Hoek, J. B., & Shulga, N. (2005). Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Research, 65, 10545–10554.PubMedCrossRef

60.

Elstrom, R. L., Bauer, D. E., Buzzai, M., Karnauskas, R., Harris, M. H., Plas, D. R., et al. (2004). Akt stimulates aerobic glycolysis in cancer cells. Cancer Research, 64, 3892–3899.PubMedCrossRef

61.

Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., et al. (2004). mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine, 10, 594–601.PubMedCrossRef

62.

Matoba, S., Kang, J. G., Patino, W. D., Wragg, A., Boehm, M., Gavrilova, O., et al. (2006). p53 regulates mitochondrial respiration. Science, 312, 1650–1653.PubMedCrossRef

63.

Kondoh, H., Lleonart, M. E., Gil, J., Wang, J., Degan, P., Peters, G., et al. (2005). Glycolytic enzymes can modulate cellular life span. Cancer Research, 65, 177–185.PubMed

64.

Levine, A. J., Feng, Z., Mak, T. W., You, H., & Jin, S. (2006). Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes and Development, 20, 267–275.PubMedCrossRef

65.

Smith, T. A., Sharma, R. I., Thompson, A. M., & Paulin, F. E. (2006). Tumor ¹⁸F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro. Journal of Nuclear Medicine, 47, 1525–1530.PubMed

66.

Riedl, C. C., Akhurst, T., Larson, S., Stanziale, S. F., Tuorto, S., Bhargava, A., et al. (2007). ¹⁸F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. Journal of Nuclear Medicine, 48, 771–775.PubMedCrossRef

67.

Gottlieb, E., & Tomlinson, I. P. (2005). Mitochondrial tumour suppressors: a genetic and biochemical update. Nature Reviews Cancer, 5, 857–866.PubMedCrossRef

68.

Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., et al. (2000). Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 287, 848–851.PubMedCrossRef

69.

Niemann, S., & Muller, U. (2000). Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nature Genetics, 26, 268–270.PubMedCrossRef

70.

Tomlinson, I. P., Alam, N. A., Rowan, A. J., Barclay, E., Jaeger, E. E., Kelsell, D., et al. (2002). Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nature Genetics, 30, 406–410.PubMedCrossRef

71.

Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., et al. (2005). Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77–85.PubMedCrossRef

72.

Bonnet, S., Archer, S. L., Allalunis-Turner, J., Haromy, A., Beaulieu, C., Thompson, R., et al. (2007). A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell, 11, 37–51.PubMedCrossRef

73.

Fantin, V. R., St-Pierre, J., & Leder, P. (2006). Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 9, 425–434.PubMedCrossRef

74.

Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., et al. (2006). Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nature Medicine, 12, 122–127.PubMedCrossRef

75.

Majhail, N. S., Urbain, J. L., Albani, J. M., Kanvinde, M. H., Rice, T. W., Novick, A. C., et al. (2003). F-¹⁸ fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. Journal of Clinical Oncology, 21, 3995–4000.PubMedCrossRef

76.

Van den Abbeele, A. D., & Badawi, R. D. (2002). Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). European Journal of Cancer, 38(Suppl 5), S60–S65.PubMed

77.

Stroobants, S., Goeminne, J., Seegers, M., Dimitrijevic, S., Dupont, P., Nuyts, J., et al. (2003). ¹⁸FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). European Journal of Cancer, 39, 2012–2020.PubMedCrossRef

78.

Cullinane, C., Dorow, D. S., Kansara, M., Conus, N., Binns, D., Hicks, R. J., et al. (2005). An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Research, 65, 9633–9636.PubMedCrossRef

79.

Su, H., Bodenstein, C., Dumont, R. A., Seimbille, Y., Dubinett, S., Phelps, M. E., et al. (2006). Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clinical Cancer Research, 12, 5659–5667.PubMedCrossRef

80.

Gatenby, R. A., & Gillies, R. J. (2007). Glycolysis in cancer: a potential target for therapy. International Journal of Biochemistry and Cell Biology, 39, 1358–1366.PubMedCrossRef

81.

Pearson, H. (2007). Cancer patients opt for unapproved drug. Nature, 446, 474–475.PubMedCrossRef

Title: Imaging of tumor glucose utilization with positron emission tomography
Authors: Andrea Buerkle
Wolfgang A. Weber
Publication date: 01-12-2008
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 4/2008
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-008-9151-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2008

Tumor detection using folate receptor-targeted imaging agents

Molecular imaging of epidermal growth factor receptor expression–activity at the kinase level in tumors with positron emission tomography

Imaging of integrin αvβ3 expression

Imaging matrix metalloproteinases in cancer

Combining anatomic and molecularly targeted imaging in the diagnosis and surveillance of embryonal tumors of the nervous and endocrine systems in children

Caveolin-1 in tumor progression: the good, the bad and the ugly

Keynote webinar | Spotlight on antibody–drug conjugates in cancer